

chain nodes :

16

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

ring/chain nodes :

17 18

chain bonds :

1-16 16-17

ring/chain bonds :

17-18

ring bonds :

1-2 1-7 2-3 2-8 3-4 3-11 4-5 5-6 6-7 6-12 7-15 8-9 9-10 10-11 12-13 13-14  
14-15

exact/norm bonds :

1-2 1-7 1-16 2-3 2-8 3-4 3-11 4-5 5-6 6-7 6-12 7-15 8-9 9-10 10-11 12-13  
13-14 14-15 17-18

exact bonds :

16-17

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS

10/086,781

=> d his

(FILE 'HOME' ENTERED AT 09:58:40 ON 28 SEP 2004)

FILE 'REGISTRY' ENTERED AT 09:58:45 ON 28 SEP 2004

L1 STRUCTURE UPLOADED  
L2 QUE L1  
L3 6 S L2  
L4 195 S L2 SSS FUL

FILE 'CAPLUS' ENTERED AT 10:03:57 ON 28 SEP 2004

L5 29 S L4  
SELECT RN L6 1-

FILE 'REGISTRY' ENTERED AT 10:04:12 ON 28 SEP 2004  
DEL SELECT

L6 1 S PYRROLIDINE/CN  
L7 1119437 S 16.136/RID  
L8 224460 S L7 AND NRS=4  
L9 8986 S L8 AND BROMO  
L10 47 S C28 H27 BR N2 O4/MF  
L11 9 S L8 AND L10  
L12 38 S L10 NOT L11  
L13 14 S L12 AND NRS=4  
L14 1150032 S METHOXYPHENYL  
L15 53015 S L7 AND L14  
L16 3 S BROMOBENZYL AND L15  
L17 4428 S 2-BROMO AND L7  
L18 155 S 4-METHOXY AND L17  
L19 45 S L18 AND NRS=4  
L20 1 S L19 AND C27 H27 BR N2 O4/MF  
L21 1 S L19 AND C27 H27 BR N2 O3 S/MF  
L22 1 S L19 AND C27 H31 BR N2 O S/MF  
L23 3 S L20 OR L21 OR L22

FILE 'CAPLUS' ENTERED AT 10:16:21 ON 28 SEP 2004


L24 2 S L23  
L25 30 S L5 OR L24

=> d l2

L2 HAS NO ANSWERS

L1 STR

10/086,781



Structure attributes must be viewed using STN Express query preparation.  
L2                    QUE   ABB=ON   PLU=ON   L1


=> d scan 123

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

10/086,781

L23 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN 2-Pyrrolidinemethanamine, N-[2-[[[2-bromophenyl)methyl]thio]phenyl]-1-  
[2-(4-methoxyphenyl)ethyl]-, (S)- (9CI)  
MF C27 H31 Br N2 O S

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2



10/086,781

L23 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN 2-Pyrrolidinecarboxamide, N-[2-[[[(2-bromophenyl)methyl]thio]phenyl]-1-  
[(4-methoxyphenyl)acetyl]-, (S)- (9CI)  
MF C27 H27 Br N2 O3 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/086,781

L23 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN 2-Pyrrolidinecarboxamide, N-[2-[(2-bromophenyl)methoxy]phenyl]-1-[(4-methoxyphenyl)acetyl]-, (2R) - (9CI)  
MF C27 H27 Br N2 O4

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10/086,781

=> d ibib abs hitstr 1-30 l25

10/086,781

L25 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:971921 CAPLUS

DOCUMENT NUMBER: 140:19879

TITLE: Drug compositions containing calcium channel antagonists exhibiting intestinal tract selectivity

INVENTOR(S): Hashimoto, Masaki; Takahashi, Kazuyoshi

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan

SOURCE: PCT Int. Appl., 126 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101490	A1	20031211	WO 2003-JP6847	20030530
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2002-160187 A 20020531

OTHER SOURCE(S): MARPAT 140:19879

AB Disclosed are a drug composition comprising a calcium channel antagonist exhibiting intestinal tract selectivity that is used for treating Alzheimer disease, mental illness, adolescent insanity, manic depression, migraine, lactation disorder, dementia, autism, hypertension, glaucoma, pain, thromboembolism, arrhythmia, epilepsy or obesity; and a serotonin liberation inhibitor comprising a calcium channel antagonist exhibiting intestinal tract selectivity. A compound (R)-3-chloro-5,11-dihydro-5-[1-(4-dimethylaminophenethyl)pyrrolidine-2-ylmethyl]dibenzo[b,e][1,4]oxazepine dihydrochloride (I) was prepared, and its effect on serotonin liberation in isolated mouse ileum was tested. A tablet containing I 50 mg/tablet was also formulated.

IT 477778-65-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(medicinal compns. containing calcium channel antagonists exhibiting intestinal tract selectivity)

RN 477778-65-7 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781



● 2 HCl


IT 477778-53-3P 477778-55-5P 477778-57-7P  
477778-61-3P 477778-63-5P 477778-69-1P  
477778-71-5P 477778-73-7P 477778-75-9P  
477778-77-1P 477778-79-3P 477778-91-9P  
477778-97-5P 630095-00-0P 630095-01-1P  
630095-02-2P 630095-03-3P 630095-18-0P  
630095-19-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(medicinal compns. containing calcium channel antagonists exhibiting intestinal tract selectivity)

RN 477778-53-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

10/086,781

RN 477778-55-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477778-57-7 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-61-3 CAPLUS

CN Benzenamine, 4-[2-[[ (2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl]-, dihydrochloride (9CI) (CA

10/086,781


INDEX NAME)

Absolute stereochemistry.



RN 477778-63-5 CAPLUS  
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinylethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477778-69-1 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



● 2 HCl

RN 477778-71-5 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 477778-73-7 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




10/086,781



● 2 HCl

RN 477778-75-9 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 477778-77-1 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

10/086,781




● 2 HCl

RN 477778-79-3 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[2-[[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 477778-91-9 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[2-[[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.

10/086,781



● 2 HCl

RN 477778-97-5 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 630095-00-0 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinylmethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/086,781



RN 630095-01-1 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 7-chloro-5,11-dihydro-5-[[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630095-02-2 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[2-(3-pyridinyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 630095-03-3 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[2-(5-pyrimidinyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 630095-18-0 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine-5(11H)-ethanamine, 3-chloro-N-[2-(5-methoxypyrazinyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)

10/086,781



RN 630095-19-1 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[6-(dimethylamino)-3-pyridinyl]ethyl]-7-fluoro-N-methyl- (9CI) (CA INDEX NAME)




IT 477778-66-8  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(medicinal comps. containing calcium channel antagonists exhibiting  
intestinal tract selectivity)  
RN 477778-66-8 CAPLUS  
CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-

10/086,781

yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 16882-89-6 221161-17-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of calcium channel antagonists exhibiting intestinal tract selectivity)

RN 16882-89-6 CAPLUS


CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 221161-17-7 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/086,781


IT 477778-54-4P 477778-56-6P 477778-58-8P  
477778-60-2P 477778-62-4P 477778-64-6P  
477778-68-0P 477778-70-4P 477778-72-6P  
477778-74-8P 477778-76-0P 477778-78-2P  
477778-80-6P 477778-92-0P 477778-98-6P  
477779-17-2P 477779-22-9P 630095-20-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of calcium channel antagonists exhibiting intestinal tract  
selectivity)

RN 477778-54-4 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[2R]-1-[2-(4-  
methoxyphenyl)ethyl]-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-56-6 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[2R]-1-[2-(4-  
methoxyphenyl)ethyl]-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/086,781



RN 477778-58-8 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477778-60-2 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 5-[[2-(1,3-benzodioxol-5-yl)ethyl]-2-pyrrolidinyl]methyl]-7-chloro-5,11-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/086,781



RN 477778-62-4 CAPLUS  
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477778-64-6 CAPLUS  
CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/086,781



RN 477778-68-0 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477778-70-4 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 477778-72-6 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-74-8 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/086,781



RN 477778-76-0 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477778-78-2 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/086,781



RN 477778-80-6 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[2R]-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 477778-92-0 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[2R]-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781




RN 477778-98-6 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 477779-17-2 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 3-chloro-5-[[[(2R)-1-[[4-(dimethylamino)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]-5,11-dihydro- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 477779-22-9 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[2R)-1-[[4-(1-pyrrolidinyl)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630095-20-4 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/086,781



REFERENCE COUNT:

98

THERE ARE 98 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/086,781

L25 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:971920 CAPLUS

DOCUMENT NUMBER: 140:19878

TITLE: Medicinal compositions containing defined calcium channel antagonists for treatment for digestive tract disease

INVENTOR(S): Yamada, Youji; Takahashi, Kazuyoshi; Hashimoto, Masaki

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan

SOURCE: PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101489	A1	20031211	WO 2003-JP6845	20030530
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2002-160188 A 20020531

OTHER SOURCE(S): MARPAT 140:19878

AB Disclosed is a medicinal composition containing defined calcium channel antagonist,

e.g. 5,11-dihydrodiaryl[b,e][1,4]oxazepine derivative, 5,11-dihydrodibenzo[b,e][1,4]thiazepine derivative, etc., having a selectivity to digestive tract. The composition is used for treatments for diseases accompanied by an organic change of the digestive tract. A compound (R)-3-chloro-5,11-dihydro-5-[1-(4-dimethylaminophenethyl)pyrrolidine-2-ylmethyl]dibenzo[b,e][1,4]oxazepine dihydrochloride (I) was prepared, and its calcium channel blocking effect on isolated colon and ileum membranes. A tablet containing I 50 mg/tablet was also formulated.

IT 477778-65-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(medicinal compns. containing defined calcium channel antagonists for treatment for digestive tract disease)

RN 477778-65-7 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781



IT 477778-54-4P 630095-20-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(medicinal compns. containing defined calcium channel antagonists for treatment for digestive tract disease)

RN 477778-54-4 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630095-20-4 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781




IT 477778-53-3P 477778-55-5P 477778-57-7P  
477778-61-3P 477778-63-5P 477778-69-1P  
477778-71-5P 477778-73-7P 477778-75-9P  
477778-77-1P 477778-79-3P 477778-91-9P  
477778-97-5P 630095-00-0P 630095-01-1P  
630095-02-2P 630095-03-3P 630095-19-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(medicinal compns. containing defined calcium channel antagonists for treatment for digestive tract disease)

RN 477778-53-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 477778-55-5 CAPLUS

10/086,781

CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477778-57-7 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-61-3 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

10/086,781


Absolute stereochemistry.



RN 477778-63-5 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-69-1 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[2-[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-], dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781




● 2 HCl

RN 477778-71-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 477778-73-7 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

10/086,781




● 2 HCl

RN 477778-75-9 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


RN 477778-77-1 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




10/086,781



RN 477778-79-3 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[2-[[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 477778-91-9 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[2-[[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


10/086,781



● 2 HCl

RN 477778-97-5 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 630095-00-0 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/086,781



RN 630095-01-1 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 7-chloro-5,11-dihydro-5-[[1-[(2R)-1-[2-(4-methoxyphenyl)ethyl]pyrrolidin-2-yl]ethyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630095-02-2 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[1-[(2R)-1-[2-(3-pyridinyl)ethyl]pyrrolidin-2-yl]ethyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 630095-03-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R)-1-[2-(5-pyrimidinyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630095-19-1 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[6-(dimethylamino)-3-pyridinyl]ethyl]-7-fluoro-N-methyl- (9CI) (CA INDEX NAME)

10/086,781




IT 477778-66-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(medicinal comps. containing defined calcium channel antagonists for  
treatment for digestive tract disease)

RN 477778-66-8 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-  
yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 630095-18-0P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)  
(nmedicinal comps. containing defined calcium channel antagonists for

10/086,781

treatment for digestive tract disease)

RN 630095-18-0 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, 3-chloro-N-[2-(5-methoxypyrazinyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



IT 16882-89-6 221161-17-7


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of medicinal compns. containing defined calcium channel antagonists

for treatment for digestive tract disease)

RN 16882-89-6 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 221161-17-7 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(2R)-2-pyrrolidinymethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781



IT 477778-56-6P 477778-58-8P 477778-60-2P  
477778-62-4P 477778-64-6P 477778-68-0P  
477778-70-4P 477778-72-6P 477778-74-8P  
477778-76-0P 477778-78-2P 477778-80-6P  
477778-92-0P 477778-98-6P 477779-17-2P  
477779-22-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of medicinal compns. containing defined calcium channel  
antagonists  
for treatment for digestive tract disease)

RN 477778-56-6 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[2R]-1-[2-(4-  
methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-58-8 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[2R]-1-[2-(4-  
methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 477778-60-2 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5-[[ (2R)-1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-pyrrolidinyl]methyl]-7-chloro-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-62-4 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/086,781



RN 477778-64-6 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-68-0 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 477778-70-4 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[ (2R) -1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-72-6 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[ (2R) -1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 477778-74-8 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[2-[[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-76-0 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[2-[[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 477778-78-2 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[2-[[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-80-6 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[2-[[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 477778-92-0 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R) -1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477778-98-6 CAPLUS


CN Dibenzo[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

10/086,781



RN 477779-17-2 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5-[[[(2R)-1-[[4-(dimethylamino)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]-5,11-dihydro- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 477779-22-9 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[[(2R)-1-[[4-(1-(dimethylamino)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781



REFERENCE COUNT:


47

THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/086,781

~~15~~ ANSWER 3 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2003:644379 CAPLUS  
DOCUMENT NUMBER: 139:173816  
TITLE: Pharmaceutical compositions containing  
(biphenylcarboxamido)isoindoline derivatives as ApoB  
secretion inhibitors and hypolipemics  
INVENTOR(S): Yamada, Harutami; Ando, Akira; Kawanishi, Hiroyuki;  
Nagata, Koichi; Yasuhara, Mikiko  
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 75 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003231633	A2	20030819	JP 2002-29596	20020206
PRIORITY APPLN. INFO.:			JP 2002-29596	20020206
OTHER SOURCE(S):	MARPAT 139:173816			
GI				



- AB The derivs., useful for treatment of hyperlipemia, ischemic heart diseases, apoplexy, obesity, adiposis, constipation, etc., contain the title compds. I [A, B = (un)substituted benzene ring; Q = CO, CH<sub>2</sub>; R = (un)substituted lower alkyl, lower alkenyl, carbamoyl, heterocyclyl, aryl] or their pharmacol. acceptable salts. 2-(2-Pyridyl)acetyl-5-[2-(4-trifluoromethylphenyl)benzoylamino]isoindoline hydrochloride (II; preparation given) inhibited ApoB secretion by HepG2 cells at IC<sub>50</sub> 2.1 nM. Oral administration of II to rats 1 h prior to loading of olive oil lowered plasma triglyceride concentration at ED<sub>50</sub> 0.59 mg/kg.
- IT **400726-74-1P**  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of (biphenylcarboxamido)isoindoline derivs. as ApoB secretion inhibitors and hypolipemics)
- RN 400726-74-1 CAPLUS
- CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethyl)-2,3-dihydro-1H-isoindol-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)




10/086,781



10/086,781

L25 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2002:927415 CAPLUS  
DOCUMENT NUMBER: 138:14080  
TITLE: Preparation of dihydrodiaryloxazepine derivatives for  
treatment of functional digestive tract diseases  
INVENTOR(S): Sakata, Katsutoshi; Tsuji, Takashi; Tokumasu,  
Munetaka; Takahashi, Kazuyoshi; Hirasawa, Shigeo;  
Ezaki, Junko  
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan  
SOURCE: PCT Int. Appl., 116 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096891	A1	20021205	WO 2002-JP5193	20020529
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1403258	A1	20040331	EP 2002-730742	20020529
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004110742	A1	20040610	US 2003-724179	20031201
PRIORITY APPLN. INFO.:			JP 2001-161988	A 20010530
			WO 2002-JP5193	W 20020529
OTHER SOURCE(S):	MARPAT 138:14080			
GI				



AB The title compds. I [ring G, J, K = benzene ring or N-containing aromatic ring; R1 - R8 = halo, H; R9 - R13 = H, halo, cyano, etc.; A = CH<sub>2</sub>, etc.; B = CO, etc.; or AB = CH:CH; D = CH<sub>2</sub>, etc.; or BD = CH<sub>2</sub>; XZ = CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, and Y = H; or YZ = CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, and X = H; further detail on X, Y, Z is given; a proviso is given] are prepared Compds. of this invention are calcium channel antagonists with selectivity for the intestinal tract (IC<sub>50</sub> values of 5.6 nM to 82.5 nM) and are useful in the treatment of functional digestive tract diseases. Formulations are given.

IT 195991-49-2P 195991-50-5P 477778-53-3P  
 477778-54-4P 477778-55-5P 477778-56-6P  
 477778-57-7P 477778-58-8P 477778-59-9P  
 477778-60-2P 477778-61-3P 477778-62-4P  
 477778-63-5P 477778-64-6P 477778-65-7P  
 477778-66-8P 477778-67-9P 477778-68-0P  
 477778-69-1P 477778-70-4P 477778-71-5P  
 477778-72-6P 477778-73-7P 477778-74-8P  
 477778-75-9P 477778-76-0P 477778-77-1P  
 477778-78-2P 477778-79-3P 477778-80-6P  
 477778-91-9P 477778-92-0P 477778-97-5P  
 477778-98-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of dihydrodiaryloxazepine derivs. for treatment of functional digestive tract diseases)

RN 195991-49-2 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/086,781



RN 195991-50-5 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 477778-53-3 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 477778-54-4 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-55-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 477778-56-6 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 2-chloro-5,11-dihydro-5-[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-57-7 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 477778-58-8 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-59-9 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5-[[ (2R)-1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-pyrrolidinyl]methyl]-7-chloro-5,11-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



● HCl

RN 477778-60-2 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 5-[[[(2R)-1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-pyrrolidinyl]methyl]-7-chloro-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-61-3 CAPLUS  
CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenzo[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/086,781



RN 477778-62-4 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidiny]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-63-5 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidiny]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 477778-64-6 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-[(3-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-65-7 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781




● 2 HCl

RN 477778-66-8 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-[(3-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-67-9 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781




● 2 HCl

RN 477778-68-0 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[2-[[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-69-1 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[2-[[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781




● 2 HCl

RN 477778-70-4 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-fluoro-5,11-dihydro-5-[[ (2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-71-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[ (2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

10/086,781




● 2 HCl

RN 477778-72-6 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 7-fluoro-5,11-dihydro-5-[[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-73-7 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[[(2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781




● 2 HCl

RN 477778-74-8 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 8-fluoro-5,11-dihydro-5-[[ (2R) -1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-75-9 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R) -1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781




● 2 HCl

RN 477778-76-0 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R)-1-[2-[4-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477778-77-1 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R)-1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/086,781



RN 477778-78-2 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[2-[[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477778-79-3 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[2-[[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Clc1ccc(cc1)N2Cc3ccccc3Oc2ccccc2N2[C@H](CCN2Cc4ccc(cc4)N5CCOCC5)C6CCCC6

RN	477778-80-6	CAPLUS
CN	Dibenz[b,e][1,4]oxazepine, 3-chloro-5,11-dihydro-5-[[ (2R)-1-[2-[4-(4-morpholinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)	


Clc1ccc(cc1)N2C3Cc4ccccc4OC3N(C2)CCN(CCC5=CC=CC=C5N6CCOCC6)C5

Page 69

10/086,781

(CA INDEX NAME)


Absolute stereochemistry.



RN 477778-92-0 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R) -1-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477778-97-5 CAPLUS


CN Dibenzo[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

10/086,781



RN 477778-98-6 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl-N-[2-[3-(1-pyrrolidinyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



IT 221161-17-7 281677-99-4

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of dihydrodiaryloxazepine derivs. for treatment of functional digestive tract diseases)

RN 221161-17-7 CAPLUS


CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781




RN 281677-99-4 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl- (9CI) (CA INDEX NAME)



IT 477779-17-2P 477779-22-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of dihydrodiaryloxazepine derivs. for treatment of functional digestive tract diseases)  
RN 477779-17-2 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 3-chloro-5-[[ (2R)-1-[[4-(dimethylamino)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]-5,11-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477779-22-9 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 2-fluoro-5,11-dihydro-5-[[ (2R)-1-[[4-(1-pyrrolidinyl)phenyl]acetyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

10/086,781

Absolute stereochemistry.



REFERENCE COUNT:

13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/086,781

L25 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:465986 CAPLUS

DOCUMENT NUMBER: 137:33327

TITLE: Process for preparing crystals of oxazepine derivatives

INVENTOR(S): Matsuzawa, Toshihiro; Sekiyama, Takaaki; Yatagai, Masanobu

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan

SOURCE: PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048120	A1	20020620	WO 2000-JP8739	20001211
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001017359	A5	20020624	AU 2001-17359	20001211

PRIORITY APPLN. INFO.:

WO 2000-JP8739

A 20001211

OTHER SOURCE(S): CASREACT 137:33327

AB This document discloses a process which comprises dissolving in a solvent a mixture of optically active 5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine (I) with optically active 5,11-dihydro-5-[1-[2-(4-methoxyphenyl)ethyl]piperidin-3-yl]dibenzo[b,e][1,4]oxazepine, adding nitric acid to the obtained solution to precipitate crystals, and separating these crystals from the resulting system.

I is a known calcium antagonist for the treatment of irritable bowel syndrome.

IT 195991-49-2P 195991-50-5P 313048-22-5P


RL: IMF (Industrial manufacture); PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(process for preparing crystals of oxazepine derivs.)

RN 195991-49-2 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/086,781



RN 195991-50-5 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 313048-22-5 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl-, mononitrate (9CI) (CA INDEX NAME)

CM 1


CRN 195991-49-2

CMF C27 H30 N2 O2



10/086,781


Absolute stereochemistry. Rotation (+).



CM 2

CRN 7697-37-2

CMF H N O3




IT 437703-61-2P 437703-62-3P 437703-63-4P

RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)

(process for preparing crystals of oxazepine derivs.)

RN 437703-61-2 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 437703-62-3 CAPLUS


CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, mononitrate (9CI) (CA INDEX NAME)

10/086,781

CM 1

CRN 437703-61-2


CMF C27 H30 N2 O2



CM 2


CRN 7697-37-2

CMF H N O3



RN 437703-63-4 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT:

1


THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/086,781

~~135~~ ANSWER 6 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:142672 CAPLUS  
DOCUMENT NUMBER: 136:200094  
TITLE: Preparation of biphenylcarboxamidoisoindoline derivatives as apolipoprotein B secretion inhibitors  
INVENTOR(S): Yamada, Harutami; Ando, Akira; Kawanishi, Hiroyuki; Nagata, Koichi; Yasuhara, Mikiko  
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 149 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014277	A1	20020221	WO 2001-JP6844	20010809
W:	AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GE, GD, GE, HR, HU, ID, IL, IN, IS, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001077728	A5	20020225	AU 2001-77728	20010809
JP 2003055345	A2	20030226	JP 2001-241482	20010809
PRIORITY APPLN. INFO.:			JP 2000-243004	A 20000810
			JP 2001-172918	A 20010607
			WO 2001-JP6844	W 20010809
OTHER SOURCE(S):	MARPAT 136:200094			
GI				



AB The title compds. I [ring A is a substituted or unsubstituted benzene ring; ring B is a substituted or unsubstituted benzene ring; Q is CO or CH<sub>2</sub>; and R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted carbamoyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like], useful as apolipoprotein B secretion inhibitors (no data), are prepared Processes for the preparation of I are claimed. For example, 2-(2-pyridyl)acetyl-5-[2-(4-trifluoromethylphenyl)benzoylamino]isoindoline was prepared

IT 400726-74-1P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

10/086,781

PREP (Preparation); USES (Uses)


EP (Preparation); USES (uses)  
(preparation of biphenylcarboxamidoisoindoline derivs. as apolipoprotein B  
secretion inhibitors)

RN 400726-74-1 CAPLUS

```

RN      400726-74-1    CAPLUS
CN      [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-dibenz[b,e][1,4]oxazepin-5(11H)-
        ylethyl)-2,3-dihydro-1H-isoindol-5-yl]-4'-(trifluoromethyl)- (9CI) (CA
        INDEX NAME)

```



REFERENCE COUNT:

77

THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10 986,781

25 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:185738 CAPLUS

DOCUMENT NUMBER: 134:222732

TITLE: Novel processes for preparing oxazepine derivatives via cyclization of 2-(2-bromobenzyloxy)aniline derivative

INVENTOR(S): Sekiyama, Takaaki; Matsuzawa, Toshihiro; Yamamoto, Takashi; Yatagai, Masanobu; Ezaki, Junko

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001017980	A1	20010315	WO 2000-JP5967	20000901
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
AU 2000068689	A5	20010410	AU 2000-68689	20000901
EP 1219611	A1	20020703	EP 2000-956884	20000901
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL	
US 2002133004	A1	20020919	US 2002-86781	20020304
PRIORITY APPLN. INFO.:			JP 1999-250298	A 19990903
			WO 2000-JP5967	W 20000901
OTHER SOURCE(S):			CASREACT 134:222732; MARPAT 134:222732	
GI				



I




II

AB Industrially advantageous processes for preparing 5-substituted-5,11-dihydrodibenz[b,e][1,4]oxazepine derivs. (I; Z = CH<sub>2</sub>; Y<sub>1</sub> = H; Y<sub>2</sub> = H, lower alkyl; or Y<sub>1</sub> and Y<sub>2</sub> together represent (CH<sub>2</sub>)<sub>3</sub> or (CH<sub>2</sub>)<sub>4</sub>; Y<sub>3</sub> = CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>; R<sub>1</sub> - R<sub>5</sub> = H, halo, lower alkyl, HO, lower alkoxy, NH<sub>2</sub>, lower alkylamino; or R<sub>1</sub> and R<sub>2</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>3</sub> and R<sub>4</sub>, or R<sub>4</sub> and R<sub>5</sub> together represents OCH<sub>2</sub>O) through intramol. arylation and reduction from [2-(2-bromobenzoyloxy)phenyl]amide derivs. bearing via amide linkage substituents to be introduced at the 5-position are described. More particularly, a process comprises subjecting (R)-1-[(4-methoxyphenyl)acetyl]pyrrolidine-2-carboxylic [2-(2-bromobenzoyloxy)phenyl]amide (II; Y<sub>1</sub>-Y<sub>3</sub>, R<sub>1</sub>-R<sub>5</sub> = same as above) to intramol. arylation to form (R)-[[2-(5,11-dihydrodibenz[b,e][1,4]oxazepine-5-carbonyl)pyrrolidin]-1-yl]-2-(4-methoxyphenyl)ethanone I (Z = CO; Y<sub>1</sub>-Y<sub>3</sub>, R<sub>1</sub>-R<sub>5</sub> = same as above) and then reducing the obtained compound. The compds. I possesses calcium channel antagonism and are useful for the prevention or treatment of digestive tract motility disorders, in particular intestinal disorders such as irritable bowel syndrome. Thus, (R)-1-[(4-methoxyphenyl)acetyl]pyrrolidine-2-carboxylic acid [2-(2-bromobenzoyloxy)phenyl]amide (preparation given) (1.69 kg), 23.0 g CuBr, and 443 g K<sub>2</sub>CO<sub>3</sub> were added to 4.19 L pyridine and heated under reflux for 100 h to give, after workup and silica gel chromatog., 1.35 kg (R)-[2-[(5,11-dihydrodibenzo[b,e][1,4]oxazepin-5-yl)carbonyl]pyrrolidin-1-yl]-2-(4-methoxyphenyl)ethanone (95% yield). A solution of the latter compound (1.35 kg) in 2.69 L THF was added to a cooled (5°) suspension of 400 g NaBH<sub>4</sub> in 19.77 L THF, treated dropwise with 1.97 kg BF<sub>3</sub>-THF complex at ≤10°, stirred at 5° for 1 h and 40° for 14 h, cooled at 5°, treated dropwise with 13.6 L 1.5 M aqueous NaOH, and stirred at 60° for 2 h. The reaction mixture was extracted with 8.1 L PhMe and the organic layer was concentrated in vacuo to .apprx.7.5 L, washed with water three times, warmed at 30°, treated dropwise with 941 L 4 M HCl/EtOAc, stirred at 5° overnight, and filtered to collect precipitated crystals which ere recrystd. from 2-propanol to give 1.00 kg (R)-(+)-5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine hydrochloride (73%).

IT 329329-17-1P 329329-18-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (novel processes for preparing oxazepine derivs. via cyclization of (bromobenzoyloxy)aniline derivative)

RN 329329-17-1 CAPLUS  
 CN 2-Pyrrolidinecarboxamide, N-[2-[(2-bromophenyl)methoxy]phenyl]-1-[(4-methoxyphenyl)acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/086,781

RN 329329-18-2 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[2R]-1-[(4-methoxyphenyl)acetyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 195991-50-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(novel processes for preparing oxazepine derivs. via cyclization of (bromobenzoyloxy)aniline derivative)

RN 195991-50-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[2R]-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/086,781

L25 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:889402 CAPLUS

DOCUMENT NUMBER: 134:42148

TITLE: Preparation of crystals of oxazepines for treatment of irritable colon syndrome

INVENTOR(S): Matsusawa, Toshihiro; Sekiyama, Takaaki; Yatagai, Masanobu

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000351778	A2	20001219	JP 1999-162760	19990609
PRIORITY APPLN. INFO.:			JP 1999-162760	19990609

OTHER SOURCE(S): CASREACT 134:42148

AB 5,11-Dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine nitrate (I), useful treatment of irritable colon syndrome, etc. (no data), is prepared by reaction of 5,11-dihydrodibenzo[b,e][1,4]oxazepine with optically active 3-chloro-1-(4-methoxyphenethyl)piperidine, reaction of the resulting mixts. containing optically active 5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine (II) and 5,11-dihydro-5-[1-[2-(4-methoxyphenyl)ethyl]piperidin-3-yl]dibenzo[b,e][1,4]oxazepine (III) in HNO<sub>3</sub> in solvents, and isolation of I by crystallization 5,11-Dihydrodibenzo[b,e][1,4]oxazepine was reacted with (S)-(+)-3-chloro-1-(4-methoxyphenethyl)piperidine in the presence of NaH in DMSO at 50° for 5 h to give 7.3:1 mixture of (R)-(+)-II and (S)-III, which was reacted with HNO<sub>3</sub> in EtOH at room temperature overnight to give 43.7% (R)-I.

IT 195991-49-2P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of crystals of oxazepines by condensation of benzooxazepine with chloropiperidine and reaction with nitric acid)


RN 195991-49-2 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



10/086,781



IT 313048-22-5P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of crystals of oxazepines by condensation of benzooxazepine with chloropiperidine and reaction with nitric acid)

RN 313048-22-5 CAPLUS


CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 195991-49-2

CMF C27 H30 N2 O2

Absolute stereochemistry. Rotation (+).




10/086,781

CM 2

CRN 7697-37-2

CMF H N O3



IT 195991-50-5P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of crystals of oxazepines by condensation of benzooxazepine with chloropiperidine and reaction with nitric acid)

RN 195991-50-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

10/086,781

L25 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:475653 CAPLUS

DOCUMENT NUMBER: 133:89556

TITLE: Preparation of oxazepine derivatives and drugs containing the same

INVENTOR(S): Sakata, Katsutoshi; Tsuji, Takashi; Sasaki, Noriko; Takahashi, Kazuyoshi

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040570	A1	20000713	WO 2000-JP71	20000111
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1142884	A1	20011010	EP 2000-900167	20000111
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 2002099047	A1	20020725	US 2001-899928	20010709
US 6528504	B2	20030304		
PRIORITY APPLN. INFO.:			JP 1999-3268	A 19990108
			JP 1999-3269	A 19990108
			JP 1999-3270	A 19990108
			WO 2000-JP71	W 20000111

OTHER SOURCE(S): MARPAT 133:89556

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. [I; A = Q, Q1, Q2; R = H, Cl, (CH<sub>3</sub>)<sub>2</sub>N, CH<sub>3</sub>O; R1 = CH<sub>3</sub>O, N(CH<sub>3</sub>)<sub>2</sub>, H; R-R1 = OCH<sub>2</sub>O; n = 2, 3; ], salts, stereoisomers, and drug compns. containing I are prepared and are useful in the treatment or prevention of motor function disorder of digestive tract, particularly intestinal diseases including irritable bowel syndrome. Thus, the title compds. (R)-5,11-Dihydro-5-[1-(4-methoxyphenethyl)-piperidin-2-ylmethyl]dibenzo[b,e][1,4] oxazepine and (R)-5,11-dihydro-5-[1-(4-dimethylaminophenethyl)-piperidin-2-ylmethyl]dibenzo[b, e][1,4]oxazepin were prepared and tested.

IT 281677-32-5P 281677-34-7P 281677-35-8P  
281677-36-9P 281677-37-0P 281677-38-1P  
281677-45-0P 281677-46-1P 281677-47-2P  
281677-48-3P 281677-49-4P 281677-50-7P  
281677-51-8P 281677-52-9P 281677-53-0P  
281677-56-3P 281677-57-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological


10/086,781

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of oxazepine derivs. and drugs containing the same)

RN 281677-32-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 281677-34-7 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2S)-1-[2-(3-methoxyphenyl)ethyl]-2-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 281677-35-8 CAPLUS

10/086,781

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R)-1-[3-(4-methoxyphenyl)propyl]-2-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 281677-36-9 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 5-[[ (2R)-1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-piperidinyl]methyl]-5,11-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 281677-37-0 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 5-[[ (2R)-1-[2-(4-chlorophenyl)ethyl]-2-piperidinyl]methyl]-5,11-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



● HCl

RN 281677-38-1 CAPLUS  
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-piperidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● 2 HCl

RN 281677-45-0 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(4-methoxyphenyl)ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/086,781




RN 281677-46-1 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine-5(1H)-ethanamine, N-[2-(3-methoxyphenyl)ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 281677-47-2 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine-5(1H)-ethanamine, N-[3-(4-methoxyphenyl)propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/086,781



RN 281677-48-3 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 281677-49-4 CAPLUS


CN Dibenzo[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(4-chlorophenyl)ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



10/086,781




RN 281677-50-7 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[4-(dimethylamino)phenyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



RN 281677-51-8 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[3-(dimethylamino)phenyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


10/086,781



RN 281677-52-9 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-piperidinyl]methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 281677-53-0 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2S)-1-[2-(3-methoxyphenyl)ethyl]-2-piperidinyl]methyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/086,781



RN 281677-56-3 CAPLUS


CN Dibenzo[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(4-methoxyphenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 281677-57-4 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(3-methoxyphenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)

10/086,781



IT 281677-61-0P 281677-64-3P 281677-67-6P  
281677-70-1P 281677-73-4P 281677-98-3P  
281677-99-4P 281678-00-0P 281678-01-1P  
281678-02-2P 281678-03-3P 281678-04-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxazepine derivs. and drugs containing the same)

RN 281677-61-0 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[2R]-1-[2-(3-methoxyphenyl)ethyl]-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 281677-64-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[2R]-1-[3-(4-methoxyphenyl)propyl]-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 281677-67-6 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5-[[[(2R)-1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-piperidinyl]methyl]-5,11-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 281677-70-1 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5-[[[(2R)-1-[2-(4-chlorophenyl)ethyl]-2-piperidinyl]methyl]-5,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/086,781

RN 281677-73-4 CAPLUS


CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-piperidinylethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 281677-98-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-acetamide, N-methyl- (9CI) (CA INDEX NAME)



RN 281677-99-4 CAPLUS


CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-methyl- (9CI) (CA INDEX NAME)



RN 281678-00-0 CAPLUS


CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[3-(4-methoxyphenyl)propyl]-N-methyl- (9CI) (CA INDEX NAME)

10/086,781



RN 281678-01-1 CAPLUS


CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(1,3-benzodioxol-5-yl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 281678-02-2 CAPLUS


CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-(4-chlorophenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)

10/086,781



RN 281678-03-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[4-(dimethylamino)phenyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 281678-04-4 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N-[2-[3-(dimethylamino)phenyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



10/086,781



IT 281677-33-6P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazepine derivs. and drugs containing the same)

RN 281677-33-6 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[[(2S)-1-[2-(4-methoxyphenyl)ethyl]-2-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT:


2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/086,781

25 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN  
 X ACCESSION NUMBER: 1999:404950 CAPLUS  
 DOCUMENT NUMBER: 131:58843  
 TITLE: preparation of 3-piperidyl-4-oxoquinazoline  
 derivatives as medicinal compositions  
 INVENTOR(S): Sato, Motohide; Katsushima, Takeo; Kinoshita, Hajime  
 PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan  
 SOURCE: PCT Int. Appl., 142 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9931085	A1	19990624	WO 1998-JP5628	19981211
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 11228569	A2	19990824	JP 1998-288979	19981012
JP 2959765	B2	19991006		
ZA 9811315	A	19990630	ZA 1998-11315	19981210
AU 9915068	A1	19990705	AU 1999-15068	19981211
AU 717963	B2	20000406		
EP 970954	A1	20000112	EP 1998-959187	19981211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
BR 9807339	A	20000321	BR 1998-7339	19981211
TR 9901933	T1	20000321	TR 1999-9901933	19981211
NZ 337118	A	20000327	NZ 1998-337118	19981211
NO 9903868	A	19991012	NO 1999-3868	19990811
US 6235730	B1	20010522	US 1999-367242	19991026
PRIORITY APPLN. INFO.:			JP 1997-362819	A 19971212
			JP 1998-288979	A 19981012
			WO 1998-JP5628	W 19981211
OTHER SOURCE(S):		MARPAT 131:58843		
GI				



AB 3-Piperidyl-4-oxoquinazoline derivs. or pharmaceutically acceptable salts [I; R = amino substituted by optionally substituted aryl, heteroaryl, or cyclic amino such as dibenzazepine; n = integer from 1 to 4; R3, R4 = H, lower alkyl, etc.], having an excellent MTP-inhibitory activity, thus


useful in inhibiting the formation of LDL causative of arteriosclerotic diseases and enabling the regulation of TG, cholesterol and lipoproteins such as LDL in the blood and cellular lipids via the regulation of the MTP activity, were prepared I are expected also as a novel type of remedies or preventives for hyperlipemia or arteriosclerotic diseases and, moreover, as remedies or preventives for pancreatitis, obesity, hypercholesterolemia, hypertriglyceridemia, etc. Refluxing a mixture of  $\text{BrCH}_2\text{CH}_2\text{NPh}_2$  and 3-(piperidin-4-yl)-3H-quinazolin-4-one containing  $\text{K}_2\text{CO}_3$  in MeCN gave 55% I ( $\text{R} = \text{Ph}_2\text{N}$ ,  $\text{R}_3 = \text{R}_4 = \text{H}$ ,  $n = 2$ ) (II). II.2HCl showed  $\text{IC}_{50}$  of  $0.1 \mu\text{M}$  against apolipoprotein B secretion and  $0.6 \mu\text{M}$  against triglyceride transport in vitro.

IT **227806-80-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 3-piperidyl-4-oxoquinazoline derivs. as medicinal compns.)

RN 227806-80-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[1-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




IT **227806-33-9P 227806-34-0P 227806-35-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-piperidyl-4-oxoquinazoline derivs. as medicinal compns.)


RN 227806-33-9 CAPLUS

CN Carbamic acid, [1-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethyl)-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 227806-34-0 CAPLUS


CN 4-Piperidinamine, 1-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethyl)- (9CI)  
(CA INDEX NAME)



RN 227806-35-1 CAPLUS

CN Benzamide, 2-amino-N-[1-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

10/086,781



REFERENCE COUNT:

18

THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/086,781

L25 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:194140 CAPLUS

DOCUMENT NUMBER: 130:223305

TITLE: Preparation and formulation of 5,11-dihydrodibenz[b,e][1,4]oxazepine derivatives as calcium antagonists

INVENTOR(S): Sakata, Katsutoshi; Tsuji, Takashi; Sasaki, Noriko; Takahashi, Kazuyoshi

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912925	A1	19990318	WO 1998-JP4071	19980910
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2304262	AA	19990318	CA 1998-2304262	19980910
AU 9890014	A1	19990329	AU 1998-90014	19980910
AU 740878	B2	20011115		
EP 1020466	A1	20000719	EP 1998-941803	19980910
EP 1020466	B1	20030219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
AT 232861	E	20030315	AT 1998-941803	19980910
US 6562808	B1	20030513	US 2000-522946	20000310
PRIORITY APPLN. INFO.:			JP 1997-245669	A 19970910
			JP 1997-245670	A 19970910
			WO 1998-JP4071	W 19980910
OTHER SOURCE(S):	MARPAT 130:223305			
GI				



AB The title compds. I [R1 - R5 = H, alkoxy, etc.; R6, R7 = H, hydroxy; Y1 = methylene, etc.] are prepared I are useful in the treatment or prevention of intestinal diseases such as gastrointestinal tract dyskinesia, in particular, irritable bowel syndrome. In an in vitro test for calcium antagonism using ileum, (R)-5,11-Dihydro-5-[1-[2-(4-dimethylaminophenyl)ethyl]-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine dihydrochloride (II) in vitro showed IC<sub>50</sub> of 35 nM; in an in vitro test for calcium antagonism using artery, II showed IC<sub>50</sub> of 255 nM. I also showed high water solubility

IT 221159-49-5P 221159-53-1P 221159-56-4P  
 221159-60-0P 221159-63-3P 221159-66-6P  
 221159-69-9P 221159-72-4P 221159-75-7P  
 221159-77-9P 221159-80-4P 221159-84-8P  
 221159-91-7P 221159-97-3P 221160-01-6P  
 221160-05-0P 221160-09-4P 221160-13-0P  
 221160-22-1P 221160-29-8P 221160-36-7P  
 221160-44-7P 221160-51-6P 221160-58-3P  
 221160-64-1P 221160-70-9P 221160-75-4P  
 221160-82-3P 221160-86-7P 221160-90-3P  
 221160-94-7P 221160-99-2P 221161-03-1P  
 221161-07-5P 221161-10-0P 221161-13-3P  
 221161-14-4P 221161-15-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of dihydrodibenzoxazepine derivs. as calcium antagonists)

RN 221159-49-5 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/086,781



RN 221159-53-1 CAPLUS  
CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 221159-56-4 CAPLUS  
CN Benzenamine, 4-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/086,781



RN 221159-60-0 CAPLUS

CN Benzenamine, 4-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 221159-63-3 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 221159-66-6 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 221159-69-9 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 221159-72-4 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(1H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 221159-75-7 CAPLUS

CN Benzenamine, 3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(1H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 221159-77-9 CAPLUS

CN Benzenamine, 3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 221159-80-4 CAPLUS

CN Benzenamine, 3-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/086,781



RN 221159-84-8 CAPLUS  
CN Benzenamine, 3-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 221159-91-7 CAPLUS  
CN Benzenamine, 3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



● 2 HCl

RN 221159-97-3 CAPLUS  
CN Benzenamine, 3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 221160-01-6 CAPLUS  
CN Benzenamine, 3-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781




● 2 HCl

RN 221160-05-0 CAPLUS

CN Benzenamine, 2-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221160-09-4 CAPLUS

CN Benzenamine, 2-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



● 2 HCl

RN 221160-13-0 CAPLUS  
CN Benzenamine, 2-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinylethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221160-22-1 CAPLUS  
CN Benzenamine, 5-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinylethyl]-2-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/086,781



RN 221160-29-8 CAPLUS  
CN Benzenamine, 5-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-2-methoxy-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 221160-36-7 CAPLUS  
CN Benzenamine, 5-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/086,781



RN 221160-44-7 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R)-1-[3-(4-methoxyphenyl)propyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 221160-51-6 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R)-1-[3-(4-methoxyphenyl)propyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781




● HCl

RN 221160-58-3 CAPLUS

CN 1-Pyrrolidinepropanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-  
α-phenyl-, (αS,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221160-64-1 CAPLUS

CN 1-Pyrrolidinepropanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-  
α-phenyl-, monohydrochloride, (αS,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781




● HCl

RN 221160-70-9 CAPLUS

CN 1-Pyrrolidinepropanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-  
α-phenyl-, (αR,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221160-75-4 CAPLUS

CN 1-Pyrrolidinepropanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-  
α-phenyl-, monohydrochloride, (αR,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781




● HCl

RN 221160-82-3 CAPLUS

CN 1-Pyrrolidineethanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)- $\alpha$ -  
[(4-methoxyphenyl)methyl]-, ( $\alpha$ R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221160-86-7 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R)-1-(3-phenyl-2-propenyl)-2-  
pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/086,781



RN 221160-90-3 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R)-1-(3-phenyl-2-propenyl)-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




● HCl

RN 221160-94-7 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenoxy)ethyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/086,781



RN 221160-99-2 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenoxy)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 221161-03-1 CAPLUS  
CN Benzenamine, 4-[3-[(2R)-2-(dibenzo[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 221161-07-5 CAPLUS

CN Benzenamine, 4-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 221161-10-0 CAPLUS

CN Benzenamine, 3-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221161-13-3 CAPLUS



10/086,781

CN Benzenamine, 3-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 221161-14-4 CAPLUS

CN Benzenamine, 3-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221161-15-5 CAPLUS

CN Benzenamine, 3-[3-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]propyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781



● 2 HCl


IT 221161-16-6P 221161-17-7P 221161-18-8P  
221161-19-9P 221161-20-2P 221161-21-3P  
221161-24-6P 221161-25-7P 221161-26-8P  
221161-29-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of dihydrodibenzoxazepine derivs. as calcium antagonists)

RN 221161-16-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-  
, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221161-17-7 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[(2R)-2-pyrrolidinylmethyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 221161-18-8 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[(2S)-2-pyrrolidinylmethyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221161-19-9 CAPLUS

CN Carbamic acid, [4-[2-[(2R)-2-(dibenzo[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 221161-20-2 CAPLUS

CN Carbamic acid, [4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221161-21-3 CAPLUS

CN Carbamic acid, [3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/086,781


Absolute stereochemistry.



RN 221161-24-6 CAPLUS

CN Carbamic acid, [3-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221161-25-7 CAPLUS

CN Carbamic acid, [3-[2-[(2S)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 221161-26-8 CAPLUS

CN Carbamic acid, [2-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221161-29-1 CAPLUS

CN Carbamic acid, [5-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-2-methoxyphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781



REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/086,781

L25 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:623166 CAPLUS

DOCUMENT NUMBER: 127:293256

TITLE: Preparation and formulation of 5,11-dihydrodibenz[b,e][1,4]oxazepine derivatives for improving the motor function of the digestive tract

INVENTOR(S): Tanaka, Yuji; Misumi, Keiji; Kawakami, Yoshinari; Moriguchi, Masahiko; Takahashi, Kazuyoshi; Okamoto, Hiroki; Kamisaki, Toshiaki; Inoue, Kimihiro; Sato, Makoto

PATENT ASSIGNEE(S): Ajinomoto, Inc., Japan

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9733885	A1	19970918	WO 1997-JP754	19970311
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
ZA 9702038	A	19970917	ZA 1997-2038	19970310
TW 479057	B	20020311	TW 1997-86102931	19970310
AU 9722335	A1	19971001	AU 1997-22335	19970311
AU 704521	B2	19990422		
EP 889043	A1	19990107	EP 1997-905478	19970311
EP 889043	B1	20010829		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI			
CN 1213371	A	19990407	CN 1997-193005	19970311
CN 1085209	B	20020522		
BR 9707962	A	19990727	BR 1997-7962	19970311
JP 3127469	B2	20010122	JP 1997-532434	19970311
AT 204871	E	20010915	AT 1997-905478	19970311
ES 2159843	T3	20011016	ES 1997-905478	19970311
PT 889043	T	20020228	PT 1997-905478	19970311
CA 2261271	C	20030916	CA 1997-2261271	19970311
NO 9804162	A	19981105	NO 1998-4162	19980910
US 6127361	A	20001003	US 1998-147012	19980911
US 6436922	B1	20020820	US 2000-597409	20000619
PRIORITY APPLN. INFO.:			JP 1996-83104	A 19960311
			WO 1997-JP754	W 19970311
			US 1998-147012	A1 19980911

OTHER SOURCE(S): MARPAT 127:293256

GI





AB The title compds. I [R<sub>1</sub>, R<sub>2</sub> = H, halo, etc.; or R<sub>1</sub>R<sub>2</sub> = O(CH<sub>2</sub>)<sub>n</sub>O; n = 1 - 3; R<sub>3</sub> = H, OH; R<sub>4</sub>, R<sub>5</sub> = H, OH; or R<sub>4</sub>R<sub>5</sub> = O] are prepared I are calcium antagonists improving the motor function of the digestive tract. In an in vitro test for calcium antagonism using guinea pig ileum fragment, (R)-(+)-5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenz[b,e][1,4]oxazepine hydrochloride (II) showed IC<sub>50</sub> of 85 nM; in the test for calcium antagonism using rat artery fragment, II showed IC<sub>50</sub> of 200 nM. II showed no anticholinergic activity. II gave better improvement of the motor function of the digestive tract than nicardipine. In the test for hypotensive activity, II showed ED<sub>50</sub> of > 1000 mg/kg p.o., vs. ED<sub>50</sub> of 4 mg/kg p.o. for nicardipine.

IT 195991-49-2P 195991-50-5P 195991-51-6P  
 195991-52-7P 195991-53-8P 195991-54-9P  
 195991-55-0P 195991-56-1P 195991-57-2P  
 195991-58-3P 195991-59-4P 195991-60-7P  
 195991-61-8P 195991-62-9P 195991-63-0P  
 195991-64-1P 195991-65-2P 195991-66-3P  
 195991-67-4P 195991-68-5P 195991-69-6P  
 195991-70-9P 196959-46-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of dihydrodibenzoxazepine derivs. for improving the motor function of the digestive tract)

RN 195991-49-2 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

10/086,781



RN 195991-50-5 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[ (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 195991-51-6 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 5-[[1-[2-(4-fluorophenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

10/086,781



RN 195991-52-7 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 5-[[1-[2-(4-fluorophenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 195991-53-8 CAPLUS  
CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-(2-phenylethyl)-2-pyrrolidinyl]methyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/086,781



RN 195991-54-9 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-(2-phenylethyl)-2-pyrrolidinyl]methyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 195991-55-0 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

10/086,781



RN 195991-56-1 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 195991-57-2 CAPLUS  
CN Benzonitrile, 4-[2-[2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/086,781



RN 195991-58-3 CAPLUS

CN Benzonitrile, 4-[2-[2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 195991-59-4 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/086,781



RN 195991-60-7 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 195991-61-8 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

10/086,781



RN 195991-62-9 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 195991-63-0 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




10/086,781



RN 195991-64-1 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(3-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 195991-65-2 CAPLUS

CN Dibenzo[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(3-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/086,781



● HCl

RN 195991-66-3 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-(2-phenylethyl)-2-pyrrolidinyl]methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 195991-67-4 CAPLUS  
CN 1-Pyrrolidineethanol, 2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)- $\alpha$ -(4-methoxyphenyl)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



● HCl

RN 195991-68-5 CAPLUS  
CN Ethanone, 2-[2-(dibenz [b,e] [1,4]oxazepin-5 (11H) -ylmethyl) -1-pyrrolidinyl] -  
1-(4-methoxyphenyl) -, monohydrochloride, (R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 195991-69-6 CAPLUS  
CN 3-Pyrrolidinol, 5-(dibenz [b,e] [1,4]oxazepin-5 (11H) -ylmethyl) -1-[2-(4-  
methoxyphenyl)ethyl] -, (3S-trans) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/086,781



RN 195991-70-9 CAPLUS

CN 3-Pyrrolidinol, 5-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 196959-46-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5-[[1-[2-(1,3-benzodioxol-5-yl)ethyl]-2-pyrrolidinyl]methyl]-5,11-dihydro-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781



● HCl

IT 195991-74-3P 195991-75-4P 195991-80-1P

195991-81-2P 196710-93-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dihydrodibenzoxazepine derivs. for improving the motor function of the digestive tract)

RN 195991-74-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)-2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-2-pyrrolidinyl]methyl]-, (2R)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195991-75-4 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[1-[2-(4-methoxyphenyl)-2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-2-pyrrolidinyl]methyl]-, (2S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/086,781



RN 195991-80-1 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5,11-dihydro-5-[[4-(methoxymethoxy)-1-[2-(4-methoxyphenyl)ethyl]-2-pyrrolidinyl]methyl]-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 195991-81-2 CAPLUS

CN 3-Pyrrolidinol, 5-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-, (3R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/086,781



RN 196710-93-7 CAPLUS

CN 3-Pyrrolidinol, 5-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-, benzoate (ester), (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/086,781

L25 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1991:429390 CAPLUS

DOCUMENT NUMBER: 115:29390

TITLE: Preparation of N-(pyrrolidinyl-or piperidinylalkyl)dibenzo[b,e][1,4]thiazepines as calcium antagonists for treatment of gastrointestinal motility disorders

INVENTOR(S): Alker, David; Bass, Robert J.; Cross, Peter Edward

PATENT ASSIGNEE(S): Pfizer Ltd., UK; Pfizer Inc.

SOURCE: Eur. Pat. Appl., 66 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 404359	A1	19901227	EP 1990-305718	19900525
EP 404359	B1	19940629		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5071844	A	19911210	US 1990-527616	19900523
CA 2017535	AA	19901127	CA 1990-2017535	19900525
CA 2017535	C	20000229		
NO 9002336	A	19901128	NO 1990-2336	19900525
AU 9055954	A1	19901129	AU 1990-55954	19900525
DD 294718	A5	19911010	DD 1990-340993	19900525
HU 58329	A2	19920228	HU 1990-3197	19900525
ES 2055867	T3	19940901	ES 1990-305718	19900525
FI 96950	B	19960614	FI 1990-2632	19900525
FI 96950	C	19960925		
CN 1047673	A	19901212	CN 1990-103954	19900526
JP 03017079	A2	19910125	JP 1990-138177	19900528
JP 05007389	B4	19930128		

PRIORITY APPLN. INFO.:





GB 1989-12303

A 19890527

OTHER SOURCE(S):

MARPAT 115:29390

GI





10/086,781

AB The title compds. [I; R1 = H, alkyl; R2 = Q1,Q2, (substituted) pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl; R3,R4 = H, alkyl, alkoxy, OH, dialkylamino, halo, CF3; X1,X2 = O, CH2; X = O, S, bond; k,m,n,q = 1,2,3; p = 0,1,2], were prepared as Ca antagonists for treatment of spasm or hypermotility of smooth muscle (no data). Thus, a prestirred mixture of 5,11-dihydrodibenzo[b,e][1,4]thiazepine and KH in DME was treated with a solution of (R)-3-chloromethyl-1-(4-methoxyphenethyl)piperidine (preparation given) in DME and the mixture was refluxed 18 h to give 12% title compds. II.


IT 133714-92-8P 133714-93-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as intermediate for dibenzothiazepine calcium antagonists)

RN 133714-92-8 CAPLUS

CN 2-Pyrrolidinemethanamine, N-[2-[[[(2-bromophenyl)methyl]thio]phenyl]-1-[2-(4-methoxyphenyl)ethyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 133714-93-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[[[(2-bromophenyl)methyl]thio]phenyl]-1-[(4-methoxyphenyl)acetyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/086,781



10/086,781

~~125~~ ANSWER 14 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1975:81187 CAPLUS

DOCUMENT NUMBER: 82:81187

TITLE: Effect of substituted dibenzoxazepines on levels of reduced glutathione and potassium ions in lenses of rabbits in vitro and of rats in vivo

AUTHOR(S): Wong, Keith K.; Wang, Geng Mei; Dreyfuss, Jacques; Schreiber, Eric C.

CORPORATE SOURCE: Dep. Drug Metab., Squibb Inst. Med. Res., New Brunswick, NJ, USA

SOURCE: Journal of Pharmaceutical Sciences (1974), 63(6), 854-7

CODEN: JPMSAE; ISSN: 0022-3549

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB Substituted dibenzoxazepines decreased the levels of K<sup>+</sup> [7440-09-7] and reduced glutathione (GSH) [70-18-8] in isolated rabbit lenses, the effects of some of the compds. correlating with their tendency to bind to erythrocyte ghosts. The dietary administration of substituted dibenzoxazepines to rats also lowered GSH levels in lenses, the response being greatest in those animals that showed the most severe morphol. changes. Measurement of GSH and K<sup>+</sup> levels in lenses may aid in preliminary determination of the cataractogenicity of the dibenzoxazepines. 4-[3-(7-Chloro-5,11-dihydrodibenz[b,e][1,4]oxazepin-5-yl)propyl]-1-piperazineethanol-HCl (I) [41296-98-4] caused the greatest decrease in GSH and K<sup>+</sup> of isolated lenses.

IT 7759-15-1 28770-47-0 52454-79-2

RL: PRP (Properties)

(potassium and reduced glutathione of eye in response to)


RN 7759-15-1 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 16882-89-6

CMF C17 H20 N2 O




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.


10/086,781



RN 28770-47-0 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, 3-chloro-N,N-dimethyl- (9CI)  
(CA INDEX NAME)



RN 52454-79-2 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, 7-chloro-N,N-dimethyl-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

10/086,781

~~1025~~ ANSWER 15 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 1974:477985 CAPLUS  
DOCUMENT NUMBER: 81:77985  
TITLE: N-Oxides of 5-(aminoalkyl)-5,11-dihydrodibenzoxazepines and 5,11-dihydrodibenzthiazepines  
INVENTOR(S): Yale, Harry L.; Bernstein, Jack  
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.  
SOURCE: U.S., 6 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3796725	A	19740312	US 1971-110327	19710127
PRIORITY APPLN. INFO.:			US 1969-655352	19690724
			US 1970-17966	19700309


AB The title compds., e.g. I (R = R1 = Me, HOCH2CH2; RR1 = (CH2)4, CH2CH2OCH2CH2, CH2CHMeCH2CH2; R2 = H, Me; n = 1,2,3; X = O, S) and II (R = H, F3C; X = O, S) were prepared by oxidation of the corresponding amines. Thus, 5,11-dihydrobenz[b,e] [1,4] oxazepine was treated with Br(CH2)3Cl followed by (HOCH2CH2)2NH to give 5,11-dihydro-5-[3-[bis(2-hydroxyethyl)amino]propyl]dibenz[b,e] [1,4]oxazepine which was oxidized with 30% H2O2 to give I [R = R1 = HOCH2CH2, R2 = H, X = O, n = 3). At 5-50 mg/kg I and II were antiarrhythmic. At 0.001-0.1% I and II eliminated S. aureus and T. mentagrophytes.

IT 16882-89-6 52694-44-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(oxidation of)


RN 16882-89-6 CAPLUS

CN Dibenz[b,e] [1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 52694-44-7 CAPLUS

CN Dibenz[b,e] [1,4]oxazepine-7-sulfonamide, 5-[2-(dimethylamino)ethyl]-5,11-dihydro- (9CI) (CA INDEX NAME)



10/086,781

IT 52694-21-0P 52694-45-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 52694-21-0 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, N-oxide,  
(2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 47132-34-3

CMF C17 H20 N2 O2




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 52694-45-8 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-7-sulfonamide, 5-[2-(dimethyloxidoamino)ethyl]-  
5,11-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



10/086,781

~~115~~ ANSWER 16 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1973:413382 CAPLUS

DOCUMENT NUMBER: 79:13382

TITLE: Distribution of dibenzoxazepines bearing the carboxamide or other side chains in ocular and other tissues of dogs

AUTHOR(S): Dreyfuss, Jacques; Shaw, James M.; Ross, John J., Jr.; Wang, Geng Mei; Wong, Keith K.; Schreiber, Eric C.

CORPORATE SOURCE: Dep. Drug. Metab., Squibb Inst. Med. Res., New Brunswick, NJ, USA

SOURCE: Journal of Pharmaceutical Sciences (1973), 62(4), 606-9

CODEN: JPMSAE; ISSN: 0022-3549

DOCUMENT TYPE: Journal

LANGUAGE: English

AB After oral or i.v. administration of labeled [4-[3-(7-chloro-5,11-dihydrodibenz[b,e][1,4]oxazepin-5-yl)propyl]-1-piperazinyl]ethanol-HCl [40671-55-4], its trifluoromethyl analog, or 5-[2-(dimethylamino)ethyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine maleate [19625-12-8] to dogs, greater concns. of radioactivity were found in the organs, especially the brain, liver, lungs, and melanin-containing portions of the eye, than in the blood. The same compds. were bound to various extents to melanin granules of beef eyeball in vitro. However, 7-chloro-5,11-dihydrodibenz[b,e][1,4]oxazepine-5-carboxamide (I) [16802-77-0] was neither localized in any tissues of the dog, relative to concns. in the blood, nor bound to melanin granules in vitro. Thus, the presence of the carboxamide side chain alters I affinity for tissues, especially those containing melanin.

IT 7759-15-1

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(metabolism of, by eye and other tissues)


RN 7759-15-1 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 16882-89-6

CMF C17 H20 N2 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.

10/086,781





10/086,781

125 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1973:111389 CAPLUS  
DOCUMENT NUMBER: 78:111389  
TITLE: 5,11-Dihydrodibenzoxazepines derivatives  
INVENTOR(S): Yale, Harry L.; Sowinski, Frances A.  
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.  
SOURCE: U.S., 8 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3714192	A	19730130	US 1970-76285	19700928
PRIORITY APPLN. INFO.:			US 1965-438406	19650309
			US 1967-668632	19670918

GI For diagram(s), see printed CA Issue.


AB (Anilinobenzyl)dihydrodibenzoxazepine I (R = Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>) and its salts, which possess hypotensive, antibacterial, antifungal, and tumor inhibition activity, was prepared by reaction of dihydrodibenzoxazepine II (R = Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>) with excess NaH and 2 equivs. Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl in refluxing THF.

IT 16882-89-6P 19625-12-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 16882-89-6 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 19625-12-8 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 16882-89-6

CMF C17 H20 N2 O




10/086,781

CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



10/086,781

~~105~~ ANSWER 18 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1972:501692 CAPLUS

DOCUMENT NUMBER: 77:101692

TITLE: 5-(Aminoalkyl)-5,11-dihydrodibenzoxazepine and  
5,11-dihydrodibenzothiazepine N-oxides with  
antibacterial and antiarrhythmic activity

PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.

SOURCE: Fr. Demande, 12 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2085631	B1	19730608	FR 1970-12720	19700408
PRIORITY APPLN. INFO.:			FR 1970-12720	19700408

GI For diagram(s), see printed CA Issue.

AB The dibenzoxazepines (I, R = H, CF<sub>3</sub>; R<sub>1</sub> = N(O)Me<sub>2</sub>, 1-methyl-3-piperidyl, Cl, 4-(2-hydroxyethyl)-1-piperazinyl; n = 1-3) were prepared Thus I (R = H, R<sub>1</sub> = 1-methyl-3-piperidyl, n = 1) was obtained by treating 5,11-dihydrodibenzo[b,e] [1,4]oxazepine with (1-methyl-3-piperidyl)-methyl chloride in the presence of NaH. I (R = H, R<sub>1</sub> = N(O)Me<sub>2</sub>, n = 2) was obtained by H<sub>2</sub>O<sub>2</sub> oxidation of I (R = H, R<sub>1</sub> = NMe<sub>2</sub>, n = 2).

IT 36693-39-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 36693-39-7 CAPLUS

CN Dibenz[b,e] [1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, 5-oxide,  
(2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 47111-46-6

CMF C17 H20 N2 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



10/086,781

~~125~~ ANSWER 19 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1972:144876 CAPLUS

DOCUMENT NUMBER: 76:144876

TITLE: Qualitative and quantitative analysis of the psychopharmaceuticals, bromazepam, sulazepam, prazepam, nitrazepam, Tegretol, Noveril, Anafranil, Etumine, and SQ-10648

AUTHOR(S): Dobrecky, Jose; Gonzalez, Beatriz; Molinari Espeche, Ana M.

CORPORATE SOURCE: Fac. Farm. Bioquim., Univ. Nac. Buenos Aires, Buenos Aires, Argent.

SOURCE: Revista de la Asociacion Bioquimica Argentina (1971), 36(196-197), 214-25

CODEN: RABAAO; ISSN: 0004-4768

DOCUMENT TYPE: Journal

LANGUAGE: Spanish


AB The title drugs were quant. and qual determined volumetrically in nonaq. media and heterogenous phases; gravimetrically with silico-tungstates; colorimetrically with reineckates, Co and K thiocyanates; and spectrophotometrically in various solvents.

IT 16882-89-6

RL: ANST (Analytical study)  
(detection and determination of)

RN 16882-89-6 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)



10/086,781

125 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1972:127032 CAPLUS

DOCUMENT NUMBER: 76:127032

TITLE: 5,11-Dihydrodibenz[b,e][1,4]oxazepine derivatives

INVENTOR(S): Yale, Harry L.

PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.

SOURCE: U.S., 4 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3631052	A	19711228	US 1970-10982	19700212
PRIORITY APPLN. INFO.:			US 1970-10982	19700212

GI For diagram(s), see printed CA Issue.

AB Antianxiety title compds. (I) were prepared NaOMe-EtOH was added dropwise to a mixture of 5-trifluoromethyl-2-hydroxyformanilide and 4-chloro-2-bromobenzyl bromide in EtOH to give 2-(4-chloro-2-bromobenzyloxy)-5-tri-fluoromethylformanilide (II). A mixture of II, DMF, K<sub>2</sub>CO<sub>3</sub>, and copper bronze was heated 3.5 hr. to give 3-chloro-5,11-dihydro-7-(trifluoromethyl)dibenz[b,e][1,4]oxazepine - 5 - carboxaldehyde, from which the formyl group was removed by reflux with 25% aqueous NaOH to give 3-chloro-5,11-dihydro-7-(trifluoromethyl)dibenz-[b,e][1,4]oxazepine (III). A mixture of III, 2-[2-(2-(dimethylamino)ethyl)piperidino]ethyl chloride-HBr, AcEt, and NaOH was refluxed 3 hr to give I (R = Cl, R<sub>1</sub> = 2-[2-(dimethylamino)-ethyl]piperidino, n = 2). Similarly prepared was I [R = H, R<sub>1</sub> = 4-(2-tetrahydropyranyloxy), n = 4] which, treated with concentrate

HCl


gave I (R = H, R<sub>1</sub> = OH, n = 4), which, treated with SOCl<sub>2</sub> gave I (R = H, R<sub>1</sub> = Cl, n = 4), which, refluxed 18 hr with 3-(2-aminobutyl)piperidine, NaI, and AcEt gave I [R = H, R<sub>1</sub> = 3-(2-aminobutyl)piperidine, n = 4]. I (R = H, R<sub>1</sub> = 4-(aminomethyl)piperidino, n = 3) was similarly prepared

IT 36080-79-2P 36412-96-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 36080-79-2 CAPLUS

CN 2-Piperidineethanamine, 1-[2-[3-chloro-7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 36412-96-1 CAPLUS


10/086,781

CN 2-Piperidineethanamine, 1-[2-[3-chloro-7-(trifluoromethyl)dibenz[b,e][1,4]  
oxazepin-5(11H)-yl]ethyl]-N,N-dimethyl-, (2E)-2-butenedioate (1:2) (9CI)  
(CA INDEX NAME)

CM 1

CRN 36080-79-2

CMF C25 H31 Cl F3 N3 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



10/086,781

225 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1972:14605 CAPLUS

DOCUMENT NUMBER: 76:14605

TITLE: 5-(Aminoalkyl)-5,11-dihydrodibenz[b,e][1,4]oxazepine  
and -thiazepine N-oxides and their acid addition salts

INVENTOR(S): Yale, Harry L.; Bernstein, Jack

PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.

SOURCE: Ger. Offen., 14 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2016356	A	19711028	DE 1970-2016356	19700406
PRIORITY APPLN. INFO.:			DE 1970-2016356	19700406

GI For diagram(s), see printed CA Issue.

AB I and their salts were prepared Thus, 5-[2-dimethylamino)ethyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine was refluxed 3.5 hr with 30% H2O2 in 95% EtOH to give I [R = (CH2)2N(O)Me2, R1 = H], which was treated with maleic acid in Me2CO to give the corresponding maleate. Similarly prepared were several other I, including I [R = 3-[4-(2-hydroxyethyl)-1-piperazinyl]propyl, R1 = CF3], its N-oxide, and N-oxide dimaleate.

IT 35019-29-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 35019-29-5 CAPLUS

CN Dibenz[b,e][1,4]-oxazepine-5(11H)-ethanamine, N,N-dimethyl-, N-oxide,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 47132-34-3

CMF C17 H20 N2 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.

10/086,781






10/086,781

125 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 1971:141906 CAPLUS  
DOCUMENT NUMBER: 74:141906  
TITLE: Adamantyl dibenzoxazepines as antihistaminic,  
antiparkinsonism tranquilizing, and sedative agents  
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.  
SOURCE: Fr. M., 7 pp.  
CODEN: FMXXAJ  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	FR 6892		19690604	FR	19670626
GI	For diagram(s), see printed CA Issue.				
AB	The title compds., e.g., I, were prepared by known reactions. Thus, 1-adamantanecarbonyl chloride was converted to the amide with 1-benzylpiperazine, the amide debenzylated with H over Pd/C, and the product reduced with LiAlH <sub>4</sub> to 1-(1-adamantylmethyl)piperazine (II). II with Cl(CH <sub>2</sub> ) <sub>3</sub> Br gave the 4-(3-chloropropyl) derivative, which reacted with the Na derivative of 5,11-dihydrodibenz[b,e][1,4]-oxazepine to give I.				
IT	<b>17972-55-3P</b> RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	17972-55-3 CAPLUS				
CN	Dibenz[b,e][1,4]oxazepine, 5-[2-(1-adamantylmethylamino)ethyl]-5,11-dihydro- (8CI) (CA INDEX NAME)				



10/086,781

15 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1970:477294 CAPLUS

DOCUMENT NUMBER: 73:77294

TITLE: Adamantane derivatives, having depressant and antihistaminic activity

INVENTOR(S): Bernstein, Jack

PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.

SOURCE: Brit., 9 pp.  
CODEN: BRXXAA


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	GB 1198852		19700715	GB	19670613
GI	For diagram(s), see printed CA Issue.				
AB	A series of title compds. was prepared Thus, ClCH <sub>2</sub> CH <sub>2</sub> COCl in C <sub>6</sub> H <sub>6</sub> added dropwise with ice-cooling to 1-(methylamino)adamantane in C <sub>6</sub> H <sub>6</sub> and the mixture refluxed 5 hr gave N-(1-adamantyl)-3-chloro-N-methylpropionamide, converted by reduction with LiAlH <sub>4</sub> in Et <sub>2</sub> O into N-(3-chloropropyl)-N-methyl-1-adamantylamine (I). NaH (50% dispersion in mineral oil) and 5,11-dihydrodibenz[b,e][1,4]oxazepine stirred 1 hr in THF with N bubbled through the mixture with dropwise addition of I in THF, and the mixture refluxed 3 hr gave 5-[3-(N-methyl-1-adamantylamino)propyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine(II). For other examples were given. Title compds. have central nervous system depressant activity and antihistaminic activity and are useful in the treatment of allergies, Parkinsonism or as tranquilizers or sedatives.				
IT	17972-55-3P 28846-19-7P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	17972-55-3 CAPLUS				
CN	Dibenz[b,e][1,4]oxazepine, 5-[2-(1-adamantylmethylamino)ethyl]-5,11-dihydro- (8CI) (CA INDEX NAME)				




RN 28846-19-7 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5-[2-(1-adamantylmethylamino)ethyl]-5,11-dihydro-, maleate (8CI) (CA INDEX NAME)

CM 1

10/086,781


CRN 17972-55-3  
CMF C26 H32 N2 O



CM 2


CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



10/086,781


~~125~~ ANSWER 24 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 1970:445482 CAPLUS  
DOCUMENT NUMBER: 73:45482  
TITLE: Novel polycyclic heterocycles. Derivatives of  
5,11-dihydrodibenz[b,e][1,4]oxazepine and  
5,11-dihydrodibenzo[b,e][1,4]thiazepine  
AUTHOR(S): Yale, Harry L.; Beer, Bernard; Pluscec, Jelka;  
Spitzmiller, Erwin R.  
CORPORATE SOURCE: Squibb Inst. for Med. Res., New Brunswick, NJ, USA  
SOURCE: Journal of Medicinal Chemistry (1970), 13(4), 713-22  
CODEN: JMCMAR; ISSN: 0022-2623  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI For diagram(s), see printed CA Issue.  
AB 5-Substituted 5,11-dihydrodibenz[b,c][1,4]oxazepines (e.g. I) and  
5,11-dihydrodibenzo[b,e][1,4]thiazepines were prepared When the  
5-substituent is 3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl and a  
substituent like Cl or CF<sub>3</sub> is in the 3 or 7 position, the compounds show  
antianxiety effects at lower doses and central nervous system depressant  
activity at higher doses. When the 5 substituent is a simple  
dialkylaminoalkyl group, the compounds are not depressants at either dose  
level, but instead are stimulants, but only at the higher dose range.  
IT 19367-70-5P 24513-28-8P 28667-31-4P  
28713-69-1P 28713-71-5P 28753-36-8P  
28770-47-0P 28770-48-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 19367-70-5 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-  
(trifluoromethyl)- (8CI) (CA INDEX NAME)



RN 24513-28-8 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-  
(trifluoromethyl)-, maleate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 19367-70-5  
CMF C20 H23 F3 N2 O




10/086,781

CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 28667-31-4 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 3-chloro-5-[2-(dimethylamino)ethyl]-5,11-dihydro-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl


RN 28713-69-1 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47339-96-8

CMF C<sub>18</sub> H<sub>19</sub> F<sub>3</sub> N<sub>2</sub> O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.

10/086,781




RN 28713-71-5 CAPLUS  
CN 1-Piperazineethanol, 4-[2-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]ethyl]-, maleate (1:2) (salt) (8CI) (CA INDEX NAME)

CM 1

CRN 47650-26-0

CMF C22 H26 F3 N3 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 28753-36-8 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 2-bromo-3-chloro-5-[2-(dimethylamino)ethyl]-5,11-dihydro-, phosphate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 28770-48-1

CMF C17 H18 Br Cl N2 O


10/086,781



CM 2


CRN 7664-38-2

CMF H3 O4 P




RN 28770-47-0 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, 3-chloro-N,N-dimethyl- (9CI)  
(CA INDEX NAME)



RN 28770-48-1 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 2-bromo-3-chloro-5-[2-(dimethylamino)ethyl]-  
5,11-dihydro- (8CI) (CA INDEX NAME)




10/086,781

~~125~~ ANSWER 25 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1970:12782 CAPLUS  
DOCUMENT NUMBER: 72:12782  
TITLE: 5-(Aminoalkyl)-5,11-dihydrodibenzoxazepines  
INVENTOR(S): Yale, Harry L.; Restivo, Albert R.  
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.  
SOURCE: Brit., 3 pp.  
CODEN: BRXXAA  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	GB 1156162		19690625	GB	19660822
GI	For diagram(s), see printed CA Issue.				
AB	The title compds. I are prepared by refluxing II with ClCH <sub>2</sub> CH <sub>2</sub> NR <sub>2</sub> . The yields are considerably increased by using excess powdered NaOH (≥4 molar equivs.) in acetone, or excess NaH (≥1.2 molar equivs.) in dry tetrahydrofuran. In an example, 10 g II (Z = H), 24 ml ClCH <sub>2</sub> CH <sub>2</sub> NMe <sub>2</sub> , and 16 g NaOH in 100 ml acetone was refluxed 2 hr. The mixture was worked up, the product dissolved in acetone and maleic acid in acetone added, then Et <sub>2</sub> O added to give 72% I (R = Me, Z = H), as the maleate m. 141-2°. Also prepared were I (R = Me, Z = CF <sub>3</sub> ), maleate, m. 166-8°, and I (R = Et, Z = CF <sub>3</sub> ), b0.2 152-7°, maleate m. 147-9°. I have physiological activity.				
IT	19367-70-5P 19442-88-7P 19442-89-8P 19625-12-8P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	19367-70-5 CAPLUS				
CN	Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)- (8CI) (CA INDEX NAME)				




RN 19442-88-7 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (8CI) (CA INDEX NAME)

CM 1

CRN 47339-96-8  
CMF C18 H19 F3 N2 O



10/086,781




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 19442-89-8 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (8CI) (CA INDEX NAME)

CM 1

CRN 19367-70-5

CMF C20 H23 F3 N2 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 19625-12-8 CAPLUS


CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

10/086,781

CM 1

CRN 16882-89-6

CMF C17 H20 N2 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



10/086,781

145 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 1968:487030 CAPLUS  
DOCUMENT NUMBER: 69:87030  
TITLE: Preparation of 5-(aminoalkyl)-5,11-dihydrodibenzoxazepines and dihydrodibenzothiazepines  
INVENTOR(S): Yale, Harry L.; Restivo, Albert R.  
PATENT ASSIGNEE(S): Squibb, E.R., and Sons, Inc.  
SOURCE: U.S., 2 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3387002	A	19680604	US 1965-488266	19650917
PRIORITY APPLN. INFO.:			US 1965-488266	19650917

GI For diagram(s), see printed CA Issue.


AB The 5-(aminoalkyl)-5,11-dihydrodibenzoxazepines (I) and 5-(aminoalkyl)-5,11-dihydrodibenzothiazepines (II) are prepared by treating 5,11-dihydrodibenzoxazepines or 5,11-dihydrodibenzothiazepines with an aminoalkyl halide and a 4 molar excess of NaOH in Me<sub>2</sub>CO or NaH in dry tetrahydrofuran (THF). Thus, I (R = Me, R<sub>2</sub> = H)-maleate (III) was prepared by refluxing 10 g. 5,11-dihydrodibenz[b,e][1,4]oxazepine, 24 ml. Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl and 16 g. powdered NaOH in 100 ml. Me<sub>2</sub>CO 2 hrs. to give 72% III, m. 141-2°. An 80% yield of the same product was obtained using a 50% dispersion of NaH in mineral oil and refluxing in dry THF under N. If THF was used in place of Me<sub>2</sub>CO with NaOH the yield was reduced to 39% and if C<sub>6</sub>H<sub>6</sub> or PhMe were used as solvents no product was obtained. A 64% yield of I (R = Me, R<sub>1</sub> = 7-CF<sub>3</sub>, R<sub>2</sub> = H)-maleate m. 166-8° and an 80% yield of I (R = Et, R<sub>1</sub> = 7-CF<sub>3</sub>, R<sub>2</sub> = H), b. 152-7°, was obtained by reacting 5,11-dihydro-7-(trifluoromethyl)dibenz[b,e][1,4]oxazepine with Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl and Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl resp. in the presence of NaOH in Me<sub>2</sub>CO. II (R = Me, R<sub>1</sub> = R<sub>2</sub> = H), b. 180° and the maleate derivative m. 154-5° were prepared from 5,11-dihydrodibenzo[b,e][1,4]thiazepine.

IT 19367-70-5P 19442-88-7P 19442-89-8P  
19625-12-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 19367-70-5 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)- (8CI) (CA INDEX NAME)




RN 19442-88-7 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (8CI) (CA INDEX NAME)

CM 1

10/086,781


CRN 47339-96-8  
CMF C18 H19 F3 N2 O



CM 2

CRN 110-16-7  
CMF C4 H4 O4


Double bond geometry as shown.



RN 19442-89-8 CAPLUS  
CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (8CI) (CA INDEX NAME)

CM 1


CRN 19367-70-5  
CMF C20 H23 F3 N2 O



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



10/086,781


RN 19625-12-8 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-,  
(2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 16882-89-6

CMF C17 H20 N2 O




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



10/086,781


~~10~~5 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 1968:443950 CAPLUS  
DOCUMENT NUMBER: 69:43950  
TITLE: 5-(Aminoalkyl)-5,11-dihydrodibenzo[b,e] [1,4]oxazepins  
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.  
SOURCE: Fr., 2 pp.  
CODEN: FRXXAK  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	FR 1491073		19670804	FR	19660109
GI	For diagram(s), see printed CA Issue.				
AB	Compds. of the general formula I are prepared from 5,11-dihydrodibenzo[b,e] [1,4]-oxazepine (II), and derivs. of II, and compds. of the general formula R <sub>2</sub> NCH <sub>2</sub> CH <sub>2</sub> Cl in Me <sub>2</sub> CO in the presence of NaOH and in tetrahydrofuran in the presence of NaH. A mixture of 10 g. II, 24 ml. Me <sub>2</sub> NCH <sub>2</sub> CH <sub>2</sub> Cl, 16 g. NaOH, and 100 ml. Me <sub>2</sub> CO is refluxed 2 hrs., cooled, and filtered; the product is treated with maleic acid to give 72% 2-(dimethylaminoethyl)-5, 11-dihydrodibenzo-[b,e] [1,4] oxazepine maleate, m. 141-2°. Similarly prepared are the following I (R <sub>1</sub> = CF <sub>3</sub> ) (R, b.p./mm., and m.p. maleate given): Me, -, 166-8°; and Et, 152-7° /0.2, 147-9°.				
IT	19367-70-5P 19442-88-7P 19442-89-8P 19625-12-8P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	19367-70-5 CAPLUS				
CN	Dibenz[b,e] [1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)- (8CI) (CA INDEX NAME)				



RN 19442-88-7 CAPLUS  
CN Dibenz[b,e] [1,4]oxazepine, 5-[2-(dimethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (8CI) (CA INDEX NAME)  
CM 1  
CRN 47339-96-8  
CMF C18 H19 F3 N2 O

10/086,781




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 19442-89-8 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-7-(trifluoromethyl)-, maleate (8CI) (CA INDEX NAME)

CM 1

CRN 19367-70-5

CMF C20 H23 F3 N2 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 19625-12-8 CAPLUS


CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

10/086,781

CM 1

CRN 16882-89-6

CMF C17 H20 N2 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.





125 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1968:95870 CAPLUS  
 DOCUMENT NUMBER: 68:95870  
 TITLE: Adamantylamino(and piperazino)-5,11-dihydrodibenz[b,e][1,4]oxazepines  
 INVENTOR(S): Bernstein, Jack  
 PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.  
 SOURCE: U.S., 4 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3338900		19670829	US	19650726
FR 1552841			FR	

GI For diagram(s), see printed CA Issue.

AB Compds. of type I [where R = R1 = H, halo, lower alkyl, Ph, alkoxy, R2 = H, halo, CF3, R3 = H, halo, CF3, alkyl, alkoxy, Me2SO2NH, CF3S, Z = amino, alkylamino, piperazino, Q = alkylene, m = 0-2, n = 1-3] having central depressant and antihistaminic activity can be prepared by reacting adamantanamine with haloacyl halide followed by reduction and condensation with 5,11-dihydrobenz[b,e][1,4]oxazepine. Thus, 37.1 g. ClCH2CH2COCl in 100 ml. dry C6H6 was added dropwise to 100 g. 1-(methylamino)adamantane (II) in C6H6, the mixture refluxed 5 hrs., washed and dried, and solvent removed to give N-(1-adamantyl)-3-chloro-N-methylpropionamide which on reduction with LiAlH4 yielded N-(3-chloropropyl)-N-methyl-1-adamantanamine (III). A mixture of 4.9 g. 5,11-dihydrodibenz[b,e][1,4]oxazepine (IV), 1.5 g. NaH (50% in mineral oil), and 50 ml. tetrahydrofuran (THF) is stirred 1 hr. under N, a solution of 18 g. III in THF added, the mixture refluxed 3 hrs. and filtered, the filtrate concentrated and diluted with Et2O, the Et2O solution

extracted with 10% H3PO4, and the acid extract made basic, extracted with Et2O, and

dried over MgSO4 to give 5-[3-(N-methyl-1-adamantylamino)propyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine; the HCl salt was prepared in the usual manner. 2-(N-Methyl-1-adamantylamino)ethanol (V) is prepared by condensation of II with ethylene oxide in THF at 70°, which on treatment with SOBr2 in CHCl3 gave N-(2-bromoethyl)-N-methyl-1-adamantylamine hydrobromide (VI). Condensation of VI and IV with NaH yields 5-[2-(N-methyl-1-adamantylamino)ethyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine. Similarly prepared were: 5-[2-(N-ethyl-3-methyl-1-adamantylamino)ethyl]-5,11-dihydrobenz[b,e][1,4]oxazepine (as maleate), 5-[3-(N-methyl-3-methoxy-1-adamantylmethylamino)propyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine (as HCl salt), 5-[3-[4-(1-adamantylmethyl)-1-piperazinyl]propyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine (as di-HCl salt), and 5-[3-[4-[2-(1-adamantyl)ethyl]-1-piperazinyl]propyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine (as di-HCl salt).


IT 17972-55-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 17972-55-3 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5-[2-(1-adamantylmethylamino)ethyl]-5,11-dihydro- (8CI) (CA INDEX NAME)

10/086,781



10/086,781

025 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1968:29690 CAPLUS

DOCUMENT NUMBER: 68:29690

TITLE: Novel polycyclic heterocycles. IV. Structure of the dimer of 5,11-dihydrodibenz[b,e][1,4]oxazepine. Infrared, proton magnetic resonance, and mass spectral studies

AUTHOR(S): Yale, Harry L.; Sowinski, Francis A.

CORPORATE SOURCE: Squibb Inst. for Med. Res., New Brunswick, NJ, USA

SOURCE: Journal of Medicinal Chemistry (1967), 10(6), 1022-5

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB In the synthesis of 5-[2-(dimethylamino)ethyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine (I), by the reaction of the anion of the heterocycle with 2-dimethylaminoethyl chloride, one of the by-products isolated from the residue from the distillation of I was identified as


5-[o-[2-(dimethylamino)-ethoxy] - N - [2 - (dimethylamino)ethyl]anilino]benzyl]5,11 - dihydrodibenz[b,e][1,4]oxazepine (II). In the absence of 2-dimethylaminoethyl chloride, the anion of the heterocycle forms the parent dimer, 5-[o-(o-hydroxyanilino)benzyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine. The ir, P.M.R., and mass spectra of these and related compds. are discussed.

IT 16882-89-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(mass spectrum and N.M.R. of)

RN 16882-89-6 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)



125 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1964:461683 CAPLUS  
 DOCUMENT NUMBER: 61:61683  
 ORIGINAL REFERENCE NO.: 61:10686g-h,10687a-b  
 TITLE: Novel polycyclic heterocycles. II. Derivatives of  
 5,11-dihydrodibenz[b,e][1,4]oxazepine  
 AUTHOR(S): Yale, Harry L.; Sowinski, Francis  
 CORPORATE SOURCE: Squibb Inst. for Med. Res., New Brunswick, NJ  
 SOURCE: Journal of Medicinal Chemistry (1964), 7(5), 609-14  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Unavailable  
 OTHER SOURCE(S): CASREACT 61:61683

GI For diagram(s), see printed CA Issue.

AB cf. CA 60, 14472f. 5,11-Dihydrodibenz[b,e][1,4]oxazepine (I) was prepared by the following sequence: o-bromobenzyl o-nitrophenyl ether → o-(o-bromobenzyloxy)aniline → 2-(o-bromobenzyloxy)formanilide → 5,11-dihydrodibenz[b,e][1,4]oxazepine-5-carboxaldehyde → I. A related synthesis gave 7-chloro-5,11-dihydrodibenz[b,e][1,4]oxazepine (II). 2-(2,4-Dichlorobenzyloxy)formanilide could not be made to cyclize. Alkylation of I and II with dialkylaminoalkyl chlorides was best carried out with NaH in Me<sub>2</sub>SO. In addition I and II were allowed to react with 3-chloropropionyl chloride and the resulting 5-(3-chloropropionyl) derivs. converted to 5-(3-monoalkyl- and 3-dialkylaminoacyl) derivs. I and COCl<sub>2</sub> gave the 5-carbonyl chloride, and this derivative with dialkylaminoalcs. and dialkylaminoalkylamines gave the corresponding urethans and carbamates, resp. 5-(3-Monoalkylaminopropyl) derivs. of I and II were prepared by reaction first with N-(3-chloropropyl)-N-methylformamide and then removal of the blocking formyl group by saponification. Several of the compds. are active as antihistamines and as antipruritic agents.

IT 7759-15-1, Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)ethyl]-5,11-dihydro-, maleate (1:1) 16882-89-6,  
 Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)ethyl]-5,11-dihydro-  
 52454-79-2, Dibenz[b,e][1,4]oxazepine, 7-chloro-5-[2-(dimethylamino)ethyl]-5,11-dihydro-, hydrochloride 98742-07-5,  
 Dibenz[b,e][1,4]oxazepine, 7-chloro-5-[2-(dimethylamino)propyl]-5,11-dihydro- 99690-03-6, Dibenz[b,e][1,4]oxazepine,  
 5-[2-(dimethylamino)propyl]-5,11-dihydro- 99750-02-4,  
 Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-, hydrochloride  
 (preparation of)


RN 7759-15-1 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl-,  
 (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 16882-89-6

CMF C17 H20 N2 O




10/086,781

CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.




RN 16882-89-6 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 52454-79-2 CAPLUS

CN Dibenz[b,e][1,4]oxazepine-5(11H)-ethanamine, 7-chloro-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 98742-07-5 CAPLUS


CN Dibenz[b,e][1,4]oxazepine, 7-chloro-5-[2-(dimethylamino)propyl]-5,11-dihydro- (7CI) (CA INDEX NAME)

10/086,781




RN 99690-03-6 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5-[2-(dimethylamino)propyl]-5,11-dihydro- (7CI)  
(CA INDEX NAME)



RN 99750-02-4 CAPLUS

CN Dibenz[b,e][1,4]oxazepine, 5-[2-(diethylamino)ethyl]-5,11-dihydro-,  
hydrochloride (7CI) (CA INDEX NAME)



●x HCl